Topics

Articles

A cross-sectional study investigates changes in Medicare Advantage enrollment among Medicare beneficiaries with end-stage renal disease in the first two years of the Act.

The Impact of the 21st Century Cures Act

This year’s conference—taking place in Washington, DC— will prioritize the tackling of business, economic, and healthcare policy obstacles when it comes to decision marking and net revenue optimization. 

Pharma KOLs to Unite at Access Insights Conference 2024

How can industry stakeholders ensure the quality and supply chain security of existing product?

Unpacking the High Cost of GLP-1 Drugs

The new vials of Zepbound are available through a new self-pay pharmacy channel, priced over 50% lower than other incretin medications for obesity. 

Lilly Introduces Single-Dose Vials of Zepbound, Expanding Access for Adults with Obesity

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

Medicare Unveils Results of First-Round Drug Price Negotiations

Managing partner at Numerof & Associates.

A lack of access could shut out patients in need of maintenance drugs for complex conditions.

Pharmacy Deserts are Becoming a National Problem

What does the legislation mean for patient access leaders, pharma brand       managers, and patient service owners? Industry experts weigh in.


The IRA’s Impact on Patient Hub, Access, and Affordability Programs

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

Who Moved My Prescription? Part V: The Many Layers of Pharmacy Crisis Point

Balancing innovation focus with optimized decision-making.


Biotech’s Achilles’ Heel

Investigators evaluate differences in end-of-life care between Medicare beneficiaries in Medicare Advantage vs. traditional Medicare. 

Market Access and Pricing